BONESUPPORT announced 12-month follow-up data from an on-going clinical trial investigating the safety and efficacy of CERAMENT|G in chronic bone infection and the completeness of bone healing after surgery. CERAMENT|G is an injectable antibiotic eluting bone substitute. The results also showed evidence of ongoing bone remodeling in 80 percent of the remaining patients.
“This evidence reinforces our belief that CERAMENT|G has the potential to impact the surgical strategy for managing osteomyelitis, by providing a more effective delivery of antibiotics with concomitant full bone healing in a one-stage procedure, thereby reducing treatment time, minimizing surgical interventions and lowering healthcare costs,” said Lloyd Diamond, CEO of BONESUPPORT.
More articles on devices:
Zimmer purchases biologic therapeutics company ETEX
Medtronic to aid Syrian refugees in Jordan
Bacterin CEO to appear on FOX Business Network’s Open Bell
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
